Nrc Health (NRC) 13F Filing Data & Analysis (Q2 2026)

NRC ranks #4084 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

126 institutions disclose a position in NRC, but none treat it as a major bet — even QV Investors Inc., its most concentrated holder, allocates just 0.6% of its own portfolio to it.

GAMMA Investing LLC has added to its NRC position for two straight quarters, increasing it by $11.6K to reach $25.4K today.

Essential Partners LLC has trimmed its NRC position for two straight quarters, cutting it by $5.8K while still holding $3.6K.

NRC is up 1.6% today, and institutions have been net buyers of $3.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

NRC posted net income of $5.6M over the trailing twelve months, and currently trades at a P/E of 81.6.

• Profitable — net income of $5.6M over the trailing twelve months
• Revenue declined 0.2% year over year
• Net income declined year over year, from $20.5M to $5.6M
• Generated $26.5M in positive operating cash flow
• Current ratio of 0.55x — below the conventional 1.5x liquidity buffer
• Liabilities run 8.64x equity — a highly leveraged balance sheet worth noting